marked.bio

Company

Fosun Pharma

4 active trials that select patients by a biomarker on marked.bio, across 2 biomarkers; 2 in phase 3.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

luvometinib 2anlotinib 1bevacizumab 1

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.

Trials

4 of 5 trials shown

  1. FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration

    Not yet recruiting Phase 3 Fosun Pharma Started 2025Primary completion 2027-04 NCT07004075

    luvometinibcarboplatintemozolomide

    KIAA1549-BRAF fusion or BRAF V600E mutation-positive.

    BRAF V600ELow-grade Glioma, Pediatric Low-grade Gliomas, pLGG With BRAF Alteration

  2. Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC

    Active, not recruiting Phase 3 Fosun Pharma Started 2021Primary completion 2025-07 NCT06569420

    ALK-positive as assessed by the Ventana immunohistochemistry (IHC) test.

    ALK fusionStatus may be outdated, last updated 2024-08-26Non-Small Cell Lung Cancer, ALK-positive, SAF-189s

  3. A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC

    Recruiting Phase 2 Fosun Pharma Started 2026Primary completion 2029-06 NCT07562581

    luvometinibanlotinib

    KRAS mutation positive.

    KRAS G12CKRAS G12DNon-small Cell Lung Caner, KRAS-mutated, Metastasis, Previous Treamted

  4. XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation

    Enrolling by invitation Phase 1/2 Fosun Pharma Started 2025Primary completion 2028-04 NCT06936527

    bevacizumabFOLFOXFOLFIRIDrug: XS-03

    Documentation of RAS mutation.

    KRAS G12CKRAS G12DColorectal Cancer, Metastatic Colorectal Cancer With RAS Mutation